Resources
With our deep research and rich experience, we provide such resources for your better understanding about CCI and Zholion.
-
Q:
How many positive controls does a method validation need?
A:It depends on your container type, product and method — there is no single number that is right for every program. In practice the set is planned across the pore sizes that bracket your method's detection limit and the container configurations in your validation matrix. Zholion helps customers scope this as part of method development support; a sensible starting point is a small set at one or two challenge sizes, scaled up once the method is fixed.
-
Q:
Does USP <1207> mandate specific instruments?
A:No. The chapters describe method families and the expectations around selecting, validating and applying them. Any deterministic instrument whose validated performance covers your integrity requirement can fit a compliant program.
-
Q:
What standard governs vacuum decay testing?
A:Vacuum decay leak testing is developed based on the ASTM F2338 test method, and USP <1207> recognizes physicochemical deterministic methods including vacuum decay for package integrity testing. Equipment should also support electronic-records compliance for GMP use.
-
Q:
What are the differences between qualification, particle (Knapp test) and function test set?
A:The function test set serves for a sort of system suitability test, i.e. this test is used to test before and after each batch whether the cameras are functioning correctly. Usually, no challenging samples are used for this, but rather unities with particles having a detection rate of 100% such as particles with a size of 1000 µm, vials with missing stoppers.Qualification test set: the qualification test set consists of product specific containers containing the product and having all known "static" defects (scratches, wrong flip-off, missing stopper,...). Usually, about 10-20% of the containers of the set have a defect. New failures or defects are added to the qualification test set.Particle test set (Knapp-Test): Sets that contain only particles. These are particles having the size from 50µm to 1000µm and consisting of different materials (plastic, the material stoppers are made of, glass, metal). Hence, they are "non-static", i.e. the defect is in the container or in the drug solution. Particle test sets are part of the qualification test set at the same time. -
Q:
How does ECA stipulate about visible particulates for injectable drugs?
A:4.3 What aspects should be considered when assessing artificially created test kits, and how should their suitability be justified?
Artificially created test kits are often used when representative production samples are unavailable, technically unsuitable, or cannot be obtained in sufficient quantity for qualification, training, or evaluation purposes.
Their suitability should be assessed based on the inspection technology used and the required level of representativeness. Artificially created defects and conforming units should exhibit optical, physical, and mechanical characteristics comparable to those of the real product under routine inspection conditions.
For AI-based inspection systems, higher requirements regarding representativeness may apply, as these systems often utilize very subtle features and characteristics to distinguish between acceptable and defective units. For example, a genuine lyophilized cake with crystalline reflective properties can generally be distinguished from a matte plaster-based imitation if these differences are visible in the image data.
If artificially created defects differ in relevant characteristics—such as texture, reflectivity, contrast, size, movement behaviour, or other optical or physical properties—there is a risk that the neural network learns features introduced by the artificial manufacturing process rather than the actual defect itself. Likewise, particle detection may be influenced by factors such as viscosity, turbidity, fill height particle size, or particle contrast. These factors should therefore be considered when assessing the suitability of artificially created test kits and may also affect the performance of conventional rule-based inspection systems.
Conventional rule-based systems are generally less susceptible to such effects because they evaluate predefined image features rather than learning complex representations. Although these approaches are often less selective and may be less suitable for highly challenging inspection tasks, they typically demonstrate greater robustness against variations or realism drifts within artificially created test kits.
Consequently, the suitability of artificially created test kits should always be justified and documented with regard to the inspection technology and the intended application. The decisive criterion is not whether defects are artificially created or taken from routine production, but whether the test kit reliably reproduces the behaviour of the final drug product under the selected inspection strategy.
-
Q:
Can one instrument test different package sizes?
A:Yes. Different package sizes and shapes can be tested by changing the test chamber, fixture or sample holder.
-
Q:
Can the vacuum decay test pharmaceutical vials?
A:Yes. Vacuum decay testing can be configured for vials containing powder, lyophilized products or medicinal liquids. A package-specific chamber is normally required.
-
Q:
Which mode can be used for flexible packaging?
A:Flexible packaging can be evaluated using Pressure Decay, Vacuum Decay, Helium Leak Detection, HVLD, or Gas Analysis, depending on the package structure and product characteristics. The final testing method should be confirmed through package evaluation and feasibility testing.
-
Q:
What is the difference between vacuum decay and pressure decay?
A:Vacuum decay detects leakage by monitoring pressure changes after a vacuum is applied around the package. Pressure decay applies positive pressure and detects leakage by measuring pressure loss.
-
Q:
What is a dual system packaging leak detector?
A:A dual system packaging leak detector integrates two leak testing technologies into one instrument. The MC-DUO(VP) combines vacuum decay and pressure decay testing, allowing it to test a wider range of rigid and flexible packages.
-
Q:
Can I get traceable data from micropipette order?
A:Yes. Zholion Micropipette Positive Control samples can be supplied with traceable calibration certificates to support quality records, validation studies, and regulatory documentation.
-
Q:
Can Zholion provide custom Micropipette Positive Control Samples?
A:Yes. Zholion can customize pore size, implantation position, according to your CCIT method and validation requirements.
-
Q:
How is Micropipette Positive Control different from Laser Drilling Positive Control?
A:Laser drilling creates a micro-hole directly on the package material, while Micropipette Positive Control uses a controlled capillary glass tube to simulate a defined leakage path. Micropipette samples are especially useful when stable, calculable leak performance is required.
-
Q:
What are Micropipette Positive Control samples used for?
A:They are used for system suitability testing, method development, method comparison, method transfer, equipment qualification, and package process assessment.
-
Q:
What is a Micropipette Positive Control?
A:A Micropipette Positive Control is a pharmaceutical package sample with a precision-bored capillary glass tube sealed inside the container. It is used to simulate a defined leak path for CCIT validation and routine system checks.
-
Q:
What container types can be used for costom CCI positive cantrol?
A:Zholion can provide CCIT Positive Control Samples for vials, ampoules, prefilled syringes, cartridges, IV bags, BFS containers, and other pharmaceutical packaging formats.
-
Q:
Can Laser Drilling Positive Control samples be compliant with USP <1207>?
A:Yes. Zholion Positive Controls for CCIT are designed to support pharmaceutical package integrity testing and help users build documentation aligned with USP <1207> expectations.
-
Q:
What are Laser-drilling Positive Control used for?
A:Laser Drilling of Pharmaceutical Packaging are used for CCIT method development, equipment qualification, routine system suitability testing, validation studies, and regulatory documentation.
-
Q:
What is a Laser Drilling Positive Control?
A:A Laser Drilling Positive Control is a pharmaceutical package sample with a precisely created micro-hole. It is used as a known defect sample to verify the sensitivity and reliability of leak test methods.
-
Q:
Why do regulatory agencies preferentially recommend deterministic test methods?
A:Regulators and pharmacopoeias preferentially recommend deterministic methods for several key advantages:
- Higher sensitivity and accuracy – can detect very small leaks relevant to product risk.
- Non‑destructive – tested samples can be released and sold (ideal for batch release and high‑value products).
- Objective, quantifiable data – supports trend analysis, statistical process control, and data integrity requirements.
- Automation and high throughput – suitable for online or at‑line QC in modern pharmaceutical manufacturing.
- While probabilistic methods retain value in certain validation contexts, deterministic methods are now the mainstream, scientifically preferred technology for CCI.

